Which pharmaceutical company develops and produces Encorafenib?

Canafenib (Encorafenib) is a targeted therapy drug targeting BRAF mutations. It is mainly used to treat malignant tumors such as melanoma and colorectal cancer with BRAF V600 mutations. The drug’s research and development background and pharmaceutical manufacturer information are of great significance for patients and medical professionals to understand its quality assurance and market sources.

Canafenib was originally developed by the American biopharmaceutical companyArray BioPharma Inc., which has long been committed to developing innovative drugs in the field of targeted therapy. Arrayhas profound technical accumulation in the development of molecular targets for tumor drugs. Canafenib was launched to the market after years of research and clinical trials on Array’s R&D platform. The drug was first approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma.

Shortly after canafenib received FDA approval, pharmaceutical giant Pfizer (Pfizer Inc.) completed its acquisition of Array BioPharma in 2019. Since then, the global market rights of canafenib have officially belonged to Pfizer. Pfizer's global drug production, sales and regulatory compliance capabilities make it easier for Canafenib to be promoted in the international market and ensure high standards of drug production quality.

Currently, Canafenib is produced and distributed globally by Pfizer. It is used in combination with another MEK inhibitor, Bimetinib (Binimetinib), to become one of the important combination options for the treatment of BRAF mutation-related tumors. With the continuous deepening of targeted drug research, the clinical application scope of canafenib is also continuously expanding, bringing new treatment hope to more tumor patients.

Reference materials:https://www.braftovi.com/